If you mean clinically proven and regulated like medication, many are not

RD, 0.08% [95% CI, 0.02 to 0.15]) Proportion of individuals with newly diagnosed AF who were initiated on oral anticoagulants was not different in the screening (n=194, 73.5%) and control (n=172, 70.8%) arms (RD, 2.7% [95% CI, 5.5 to 10.4] 78.9 to 81.8% of participants treated with tirzepatide reported at least one adverse event that emerged during the treatment period as compared with 72.0% of participants in the placebo group Most frequently reported adverse events were gastrointestinal (nausea, diarrhea, and constipation) Serious adverse events were reported by 160 participants (6.3%) overall Approximately 21% of serious adverse events were considered to be related to coronavirus disease 2019 (Covid-19), which affected participants in all treatment groups Eleven deaths were reported: 4 (0.6%) in the 5-mg tirzepatide group, 2 (0.3%) in the 10-mg group, 1 (0.2%) in the 15-mg group, and 4 (0.6%) in the placebo group Four reported cases of adjudication-confirmed pancreatitis, evenly distributed across treatment groups, including the placebo group (none severe) No cases of medullary thyroid cancer were reported Reported incidence of cholelithiasis was similar among the tirzepatide and placebo groups Cholecystitis and acute cholecystitis were reported more frequently in the tirzepatide groups than in the placebo group Conclusions In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight

Monitoring these parameters more frequently during the first 8 to 12 weeks of the transition provides safety data and early detection of any issues that need adjustment
These mechanisms act under both redox-sensitive and -insensitive conditions, influencing NRF2 at the transcriptional, post-transcriptional, and post-translational levels, and involving a range of proteins and epigenetic factors such as DNA methylation, histone modifications, and microRNA (Bryan et al
[13] [18] Anti-Inflammatory and Neuroprotective Effects Reduces pro-inflammatory cytokines (TNF-, IL-6) and promotes M1-to-M2 macrophage shift
Semaglutide, marketed under the brand names Ozempic, Wegovy, and Rybelsus, is a GLP-1 agonist available in various forms, including weekly injections (Ozempic for diabetes and Wegovy for obesity) and daily oral tablets (Rybelsus)